Apellis Pharmaceuticals Inc logo

APLS - Apellis Pharmaceuticals Inc Share Price

$46.29 0.6  1.3%

Last Trade - 25/01/21

Sector
Healthcare
Size
Large Cap
Market Cap £2.53bn
Enterprise Value £2.25bn
Revenue £472k
Position in Universe 1657th / 6623
Bullish
Bearish
Unlock APLS Revenue
Momentum
Relative Strength (%)
1m -21.0%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 81.9 68.2
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, ApellisPharmaceuticals Inc revenues increased from $0K to $646K.Net loss increased from $191.5M to $423.1M. Revenuesreflect an increase in demand for the Company's productsand services due to favorable market conditions. Higher netloss reflects Research and Development - Balancing valincrease of 63% to $194.6M (expense), General andAdministrative increase from $39.6M to $94.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

APLS Revenue Unlock APLS Revenue

Net Income

APLS Net Income Unlock APLS Revenue

Normalised EPS

APLS Normalised EPS Unlock APLS Revenue

PE Ratio Range

APLS PE Ratio Range Unlock APLS Revenue

Dividend Yield Range

APLS Dividend Yield Range Unlock APLS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APLS EPS Forecasts Unlock APLS Revenue
Profile Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated September 25, 2009
Public Since November 9, 2017
No. of Shareholders: 24
No. of Employees: 350
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 75,736,924
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APLS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for APLS
Upcoming Events for APLS
Thursday 25th February, 2021 Estimate
Q4 2020 Apellis Pharmaceuticals Inc Earnings Release
Tuesday 27th April, 2021 Estimate
Q1 2021 Apellis Pharmaceuticals Inc Earnings Release
Frequently Asked Questions for Apellis Pharmaceuticals Inc
What is the Apellis Pharmaceuticals Inc share price?

As of 25/01/21, shares in Apellis Pharmaceuticals Inc are trading at $46.29, giving the company a market capitalisation of £2.53bn. This share price information is delayed by 15 minutes.

How has the Apellis Pharmaceuticals Inc share price performed this year?

Shares in Apellis Pharmaceuticals Inc are currently trading at $46.29 and the price has moved by 8.02% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Apellis Pharmaceuticals Inc price has moved by -7.62% over the past year.

What are the analyst and broker recommendations for Apellis Pharmaceuticals Inc?

Of the analysts with advisory recommendations for Apellis Pharmaceuticals Inc, there are there are currently 6 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Apellis Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Apellis Pharmaceuticals Inc next release its financial results?

Apellis Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Apellis Pharmaceuticals Inc dividend yield?

Apellis Pharmaceuticals Inc does not currently pay a dividend.

Does Apellis Pharmaceuticals Inc pay a dividend?

Apellis Pharmaceuticals Inc does not currently pay a dividend.

When does Apellis Pharmaceuticals Inc next pay dividends?

Apellis Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Apellis Pharmaceuticals Inc shares?

To buy shares in Apellis Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Apellis Pharmaceuticals Inc?

Shares in Apellis Pharmaceuticals Inc are currently trading at $46.29, giving the company a market capitalisation of £2.53bn.

Where are Apellis Pharmaceuticals Inc shares listed? Where are Apellis Pharmaceuticals Inc shares listed?

Here are the trading details for Apellis Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: APLS
What kind of share is Apellis Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Apellis Pharmaceuticals Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Apellis Pharmaceuticals Inc share price forecast 2021?

Shares in Apellis Pharmaceuticals Inc are currently priced at $46.29. At that level they are trading at 37.13% discount to the analyst consensus target price of 0.00.

Analysts covering Apellis Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -6.343 for the next financial year.

How can I tell whether the Apellis Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Apellis Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 37.5%. At the current price of $46.29, shares in Apellis Pharmaceuticals Inc are trading at 25.88% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Apellis Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Apellis Pharmaceuticals Inc.

Who are the key directors of Apellis Pharmaceuticals Inc?

Apellis Pharmaceuticals Inc's management team is headed by:

Alec Machiels - IND
Cedric Francois - PRE
Pascal Deschatelets - CFD
Federico Grossi - OTH
Nicole Perry - VFN
David Watson - VPR
Gerald Chan - CHM
A. Sinclair Dunlop - IND
Stephanie O'Brien - IND
Timothy Sullivan - CFO
Lukas Scheibler - OTH
Thomas Lackner - SVP
Paul Fonteyne - IND
Victoria Brown - SVP
Who are the major shareholders of Apellis Pharmaceuticals Inc?

Here are the top five shareholders of Apellis Pharmaceuticals Inc based on the size of their shareholding:

Morningside Venture Investments, Ltd. Corporation
Percentage owned: 16.58% (12.6m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 13.8% (10.5m shares)
Hillhouse Capital Advisors, Ltd. Investment Advisor/Hedge Fund
Percentage owned: 6.64% (5.03m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 5.7% (4.32m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.66% (4.29m shares)
Similar to APLS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.